Data from this current study indicates that primary breast tumors increased in both tumor volume and metastases as a function of time and that PLD-specific inhibitors decreased both of these factors, which strongly suggests PLD2 has a role in breast tumor progression. The gene discussed is GPLD1; the disease is neoplasm.